Does magnesium help depression?
Yes. In an open-label randomized crossover trial, six weeks of magnesium chloride improved depression scores by a net 6.0 points on the PHQ-9, with anxiety scores improving by a net 4.5 points on the GAD-7. The trial ran in 112 adults with mild-to-moderate depression who provided analyzable data, and effects were observed within two weeks.
The comparison period was no treatment rather than a placebo pill, so some of that benefit may reflect expectation rather than magnesium itself.
What the data show:
- Effectiveness: Net PHQ-9 improvement of -6.0 points (CI -7.9, -4.2; p<0.001) and net GAD-7 improvement of -4.5 points (CI -6.6, -2.4; p<0.001)
- Speed of response: Effects were observed within two weeks
- Study scope: Open-label randomized crossover trial in outpatient primary care, 126 adults enrolled, 112 analyzed
- Tolerability: Well tolerated, with 83% adherence by pill count and 61% of participants saying they would use magnesium in the future
A randomized crossover clinical trial published in PLOS ONE found that over-the-counter magnesium chloride improved depression and anxiety symptoms in adults with mild-to-moderate depression, with similar effects regardless of age, gender, baseline severity, baseline magnesium level, or use of antidepressant treatments.
Dr. Kumar’s Take
This trial is useful because it moves beyond observational association and actually gives people the supplement. The biological rationale for magnesium in mood is reasonable: it participates in neurotransmitter function, nerve transmission, and stress response regulation, and low magnesium can produce symptoms that overlap with depression, including anxiety, irritability and fatigue.
I want to be precise about what kind of evidence this is. It was open-label, and the control condition was six weeks of no treatment, not a placebo. Every participant knew when they were taking magnesium. That design cannot separate the drug effect from the expectation of taking something, and the improvement it reported is large enough that I would expect some of it to come from knowing you are being treated. What the trial does establish well is feasibility and tolerability: an inexpensive over-the-counter supplement, taken by primary care patients for six weeks, with good adherence and no need for close monitoring for toxicity. I read it as a reason to consider magnesium as an adjunct in mild-to-moderate symptoms, not as proof of a specific antidepressant effect.
Study Snapshot
This was an open-label, blocked, randomized, crossover trial carried out in outpatient primary care clinics. It enrolled 126 adults, mean age 52 and 38% male, who were diagnosed with depression and currently experiencing mild-to-moderate symptoms with PHQ-9 scores of 5 to 19. Rather than assigning separate groups to drug and placebo, each participant went through both conditions: six weeks of active treatment with 248 mg of elemental magnesium per day as magnesium chloride, and six weeks of control with no treatment. Assessments were completed at bi-weekly phone calls, and the primary outcome was the net difference in the change in depression symptoms from baseline to the end of each treatment period. Secondary outcomes included anxiety symptoms, adherence, adverse effects, and intention to use magnesium in the future.
Results in Real Numbers
The trial ran between June 2015 and May 2016. Of the 126 adults enrolled, 112 provided analyzable data. Participants had a mean age of 52 years and 38% were male.
Six weeks of magnesium chloride produced a net improvement in PHQ-9 scores of -6.0 points (CI -7.9, -4.2; p<0.001) and a net improvement in GAD-7 anxiety scores of -4.5 points (CI -6.6, -2.4; p<0.001), both measured against the no-treatment control periods. Effects were observed within two weeks. Similar effects were seen regardless of age, gender, baseline severity of depression, baseline magnesium level, or use of antidepressant treatments.
Average adherence was 83% by pill count. The supplements were well tolerated, and 61% of participants reported they would use magnesium in the future.
Who Benefits Most
The population studied here was adults in primary care with mild-to-moderate depressive symptoms, PHQ-9 scores between 5 and 19. That is who the result applies to. Notably, benefit did not depend on baseline magnesium level, so this was not limited to people who started out deficient, and it did not depend on whether participants were already taking antidepressants, which makes it relevant as an add-on rather than only as a standalone option.
People looking for a low-cost, well-tolerated option that does not require close monitoring for toxicity are the practical audience for this finding.
Safety, Limits, and Caveats
The biggest limitation is the design. This was open-label with a no-treatment control, so participants knew which period they were in, and the trial cannot separate a true drug effect from placebo response. A blinded, placebo-controlled trial would be needed for that.
The trial tested one form and one dose: 248 mg of elemental magnesium per day as magnesium chloride, over six weeks. Results may not transfer to other salts, other doses, or longer use. The enrolled population had mild-to-moderate symptoms, so this says nothing about severe depression. Longer-term effects and optimal treatment duration were not addressed by a six-week treatment period.
Practical Takeaways
- Treat magnesium as a reasonable, low-risk adjunct for mild-to-moderate depressive symptoms, not as a replacement for established treatment
- The tested regimen was 248 mg of elemental magnesium per day, given as magnesium chloride, for six weeks
- Benefit in this trial appeared within two weeks, so a short trial period is enough to judge whether it is doing anything for you
- Adherence matters: participants in this study took about 83% of their pills
- Discuss magnesium with your clinician, particularly if you have kidney disease or take medications whose absorption magnesium can affect
What This Means for Depression Treatment
An inexpensive over-the-counter supplement improved depression and anxiety scores in primary care patients with mild-to-moderate symptoms, worked within two weeks, and was well tolerated without close monitoring for toxicity. That is worth knowing.
I would hold the strength of the claim to what the design supports. Because there was no placebo arm and no blinding, this is encouraging evidence for a cheap adjunct rather than definitive proof that magnesium itself is the active ingredient in the improvement.
Related Studies and Research
Episode 31: Depression Explained, The Biology Behind the Darkness
Episode 32: Depression Recovery Roadmap: A Step-by-Step, Evidence-Based Plan
Creatine Supplementation in Depression: Review of Mechanisms
FAQs
How strong is the evidence for magnesium in depression?
This was a randomized crossover trial, but it was open-label and the comparison was six weeks of no treatment rather than placebo. It shows a large net improvement in PHQ-9 scores, and it cannot rule out that some of that improvement came from knowing you were being treated.
What type of magnesium was used in this study?
Magnesium chloride, an over-the-counter product, at 248 mg of elemental magnesium per day.
How quickly does magnesium work for depression?
Effects were observed within two weeks in this trial.
Bottom Line
In an open-label randomized crossover trial, 248 mg of elemental magnesium per day as magnesium chloride improved PHQ-9 scores by a net 6.0 points and GAD-7 scores by a net 4.5 points in adults with mild-to-moderate depression, within two weeks and with good tolerability. The authors concluded magnesium is effective for mild-to-moderate depression in adults. Because the control was no treatment rather than placebo, I would call this a promising, low-risk adjunct rather than settled evidence.
